Biomarin Pharmaceutical (BMRN) Total Debt Growth (3y) (2015 - 2025)
Biomarin Pharmaceutical (BMRN) Total Debt Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 50.25% |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 25.25% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.07% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 234.71% |
| Jun 30, 2024 | 148.62% |
| Mar 31, 2024 | 152.22% |
| Dec 31, 2022 | -64.69% |
| Sep 30, 2022 | 41.45% |
| Jun 30, 2022 | 44.51% |
| Mar 31, 2022 | -10.12% |
| Dec 31, 2021 | -17.52% |
| Sep 30, 2021 | -17.62% |
| Jun 30, 2021 | -25.05% |
| Mar 31, 2021 | -20.62% |
| Mar 31, 2020 | 153.39% |
| Dec 31, 2019 | 98.42% |
| Sep 30, 2019 | -23.64% |
| Jun 30, 2019 | -25.92% |
| Mar 31, 2019 | -3.29% |
| Dec 31, 2018 | 56.37% |
| Sep 30, 2018 | -2.94% |
| Jun 30, 2018 | -5.76% |
| Mar 31, 2018 | -6.47% |